The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.45
Bid: 9.10
Ask: 9.80
Change: -0.10 (-1.05%)
Spread: 0.70 (7.692%)
Open: 9.55
High: 9.55
Low: 9.45
Prev. Close: 9.55
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Scancell shares slip as losses widen in first half

Thu, 31st Jan 2019 09:48

(Sharecast News) - Cancer immunotherapies developer Scancell Holdings issued its interim results for the six months ended 31 October on Thursday, reporting a loss of £3.24m, widening from £2.02m year-on-year.The AIM-traded firm said its cash balance as at period end was £7.6m, down from £10.3m at the start of the half.It did raise a total of £8.0m net of expenses during the six months, which comprised £1.1m raised in an open offer to shareholders in May, and a placing of £6.9m at the end of the previous financial year.On the operational front, Scancell was granted a patent in Europe for its 'Moditope' technology, which the board said provided "broad protection" for its pipeline of Moditope vaccines.It also expanded its strategic research collaboration with the Rheumatology Unit at the Karolinska Institute, to explore the potential of Moditope to develop multiple immunotherapeutic agents for a range of different cancers.Pre-clinical development was underway with Modi-2, including progress made in the characterisation of specific homocitrullinated peptides for clinical development, the board reported, where there was the potential to address different cancer indications to Modi-1, including tumours with a "particularly immunosuppressive" environment.Scancell and Ichor continued to work with the FDA during the half-year to provide the additional information requested in response to the Investigational New Drug application submitted for the SCIB1 Phase 2 checkpoint inhibitor combination study, the board confirmed.The company also exercised its option to a worldwide commercial licence for the use of Ichor Medical Systems' 'TriGrid 2.0' electroporation delivery system with SCIB1, which would enable Scancell to use the system for its planned Phase 2 checkpoint inhibitor combination study with SCIB1.Since the period ended, the board confirmed the appointments of Dr Samantha Paston as head of research, and Dr Adrian Parry as head of manufacturing."We are pleased to report another six months of progress at Scancell," said chief executive officer Cliff Holloway."The funds raised at the end of the previous financial year and the beginning of this period will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic."Holloway said the company was working closely with Ichor and the FDA to provide the additional information requested for the initiation of its Phase 2 checkpoint inhibitor combination study of SCIB1 in patients with advanced melanoma."With our new hires and recent funding, we believe we are in a strong position to progress our pipeline of immunotherapy products through the next stage of development."As at 0914 GMT, shares in Scancell Holdings were down 4.88% at 7.11p.
More News
29 Aug 2023 14:27

Scancell appoints healthcare finance veteran as new CFO

(Sharecast News) - Immunotherapy developer Scancell announced the appointment of Sath Nirmalananthan as its new chief financial officer on Tuesday, effective immediately.

Read more
29 Aug 2023 09:53

IN BRIEF: Scancell appoints Prenetics' Sath Nirmalananthan as new CFO

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Hires Sath Nirmalananthan to be chief financial officer, starting immediately. Nirmalananthan previously was CFO for Europe, Middle East & Africa at Prenetics Ltd, a genomics-driven health sciences company. His appointment at Scancell follows Keith Green's retirement as director of finance.

Read more
31 Jul 2023 10:46

AIM WINNERS & LOSERS: Aptamer reshuffles board; Scancell expands trial

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
31 Jul 2023 10:23

Scancell shares jump on trial expansion for Modi-1 vaccine

(Alliance News) - Scancell Holdings PLC on Monday said it has expanded its Modi-1 trial for the use of checkpoint inhibitors on cancer patients.

Read more
10 Jul 2023 11:45

IN BRIEF: Scancell to focus on cancer vaccine assets amid trial data

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Will focus on lead cancer vaccine assets SCIB1 and Modi-1 following encouraging data from clinical trials. Adds phase two single arm scope trial investigating the safety and tolerability of using SCIB1 in combination with checkpoint inhibitors in patients with advanced melanoma is progressing well and notes a potential pathway for a registration trial. Adds it is fully funded to the second half of 2024 due to its increasing focus on the two clinical assets.

Read more
2 Jun 2023 13:18

Scancell to present positive recent findings at oncology summit

(Sharecast News) - Immunotherapy developer Scancell said on Friday that it is set to present an informative poster at the American Society of Clinical Oncology Meeting (ASCO) 2023 annual meeting in Chicago from 2 to 6 June.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
21 Feb 2023 12:14

Scancell shares jump on positive cancer vaccine progress

(Sharecast News) - Immunotherapy developer Scancell announced the completion of the monotherapy dose-finding arm of the phase 1 and 2 'ModiFY' clinical trial on Tuesday.

Read more
21 Feb 2023 11:56

Scancell shares up on encouraging data from ModiFY cancer trial

(Alliance News) - Scancell Holdings PLC on Tuesday said that it has completed the monotherapy dose finding arm of its multicentre Phase 1/2 ModiFY clinical trial, designed to treat cancer patients.

Read more
13 Feb 2023 11:38

Scancell gets positive result from needle-free Covid vaccines trial

(Alliance News) - Scancell Holdings PLC on Monday reported a positive response in its 'Covidity' trial, which aims to deliver needle-free injectable Covid vaccines.

Read more
1 Feb 2023 21:41

TRADING UPDATES: PetroNeft extends maturity; NetScientific loses chair

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
25 Jan 2023 14:43

TRADING UPDATES: Van Elle and Hargreaves Services post profit rises

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
18 Jan 2023 15:50

UK earnings, trading statements calendar - next 7 days

Thursday 19 January 
AJ Bell PLCTrading Statement
Bakkavor Group PLCTrading Statement
BHP Group LtdTrading Statement
boohoo Group PLCTrading Statement
Centamin PLCTrading Statement
Deliveroo PLCTrading Statement
Dunelm Group PLCTrading Statement
Energean PLCTrading Statement
Frontier Developments PLCHalf Year Results
Harbour Energy PLCTrading Statement
Headlam Group PLCTrading Statement
Ilika PLCHalf Year Results
Kier Group PLCTrading Statement
Luceco PLCTrading Statement
Network International Holdings PLCTrading Statement
Premier Foods PLCTrading Statement
Sage Group PLCTrading Statement
Zotefoams PLCTrading Statement
Friday 20 January 
4imprint Group PLCTrading Statement
Close Brothers Group PLCTrading Statement
Goldplat PLCFull Year Results
Ninety One PLCTrading Statement
Workspace Group PLCTrading Statement
PensionBee Group PLCTrading Statement
TheWorks.co.uk PLCHalf Year Results
Monday 23 January 
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Tuesday 24 January 
Accrol Group Holdings PLCHalf Year Results
Associated British Foods PLCTrading Statement
Henry Boot PLCTrading Statement
Oxford BioDynamics PLCFull Year Results
Saga PLCTrading Statement
Staffline Group PLCTrading Statement
Sureserve Group PLCFull Year Results
Velocity Composites PLCFull Year Results
Wednesday 25 January 
CMC Markets PLCTrading Statement
Conduit Holdings LtdTrading Statement
easyJet PLCTrading Statement
Forterra PLCTrading Statement
Hargreaves Services PLCHalf Year Results
hVIVO PLCTrading Statement
JD Wetherspoon PLCTrading Statement
Keywords Studios PLCTrading Statement
Quilter PLCTrading Statement
Scancell Holdings PLCHalf Year Results
Tullow Oil PLCTrading Statement
Van Elle Holdings PLCHalf Year Results
Watkin Jones PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
7 Nov 2022 12:56

Scancell in-licences SNAPvax technology for its Modi-2 cancer treatment

(Alliance News) - Scancell Holdings PLC on Monday said it has in-licensed SNAPvax technology from Vaccitech PLC to help develop its cancer treatments.

Read more
7 Nov 2022 09:29

Scancell licenses Vaccitech IP for its next vaccine candidate

(Sharecast News) - Scancell has in-licensed 'SNAPvax' technology from clinical-stage biopharmaceutical company Vaccitech, it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.